Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants

被引：20
作者：
Almeida, Volia De Carvalho [1 ]
Mussi-Pinhata, Marisa Marcia [2 ]
Sandoval De Souza, Cleonice Barbosa [2 ]
Kubo, Christina Arslanian [3 ]
Martinez, Edson Zangiacomi [4 ]
Carneiro-Sampaio, Magda Maria [5 ]
Duarte, Geraldo [6 ]
机构：
[1] Univ Fed Sao Carlos, Biol & Hlth Sci Ctr, Dept Med, BR-13565905 Sao Carlos, SP, Brazil
[2] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[3] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil
[4] Univ Sao Paulo, Dept Social Med, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[5] Univ Sao Paulo, Dept Pediat, Fac Med, BR-05403900 Sao Paulo, Brazil
[6] Univ Sao Paulo, Dept Gynecol & Obstet, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
来源：
VACCINE | 2009年 / 27卷 / 29期
基金：
巴西圣保罗研究基金会;
关键词：
Pneumococcal polysaccharide vaccine; HIV-infected pregnant woman; Passively acquired pneumococcal antibodies; MATERNAL IMMUNIZATION; STREPTOCOCCUS-PNEUMONIAE; PLACENTAL-TRANSFER; 22F POLYSACCHARIDE; CONJUGATE VACCINE; VIRAL LOAD; SERUM IGG; DISEASE; ADULTS; TRANSMISSION;
D O I：
10.1016/j.vaccine.2009.04.018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 613, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3856 / 3861
页数：6
相关论文
共 50 条
  • [21] The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
    Goldblatt, David
    Southern, Jo
    Andrews, Nick
    Ashton, Lindsey
    Burbidge, Polly
    Woodgate, Sarah
    Pebody, Richard
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1318 - 1325
  • [22] A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
    MacIntyre, C. Raina
    Ridda, Iman
    Gao, Zhanhai
    Moa, Aye M.
    McIntyre, Peter B.
    Sullivan, John S.
    Jones, Thomas R.
    Hayen, Andrew
    Lindley, Richard I.
    PLOS ONE, 2014, 9 (04):
  • [23] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility
    Valenzuela B., M. Teresa
    Altuzarra H., Rogelio
    Trucco A., Olivia
    Villegas R., Rodrigo
    Inostroza S., Jaime
    Granata S., Paulo
    Fleiderman V., Jose
    Maggi C., Leonardo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (03) : 322 - 326
  • [24] IMMUNOGENICITY AND SAFETY OF A 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN HEALTHY-CHILDREN AND IN CHILDREN AT INCREASED RISK OF PNEUMOCOCCAL INFECTION
    LEE, HJ
    KANG, JH
    HENRICHSEN, J
    KONRADSEN, HB
    JANG, SH
    SHIN, HY
    AHN, HS
    CHOI, Y
    HESSEL, L
    NAM, SW
    VACCINE, 1995, 13 (16) : 1533 - 1538
  • [25] Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants
    Madhi, Shabir A.
    Izu, Alane
    Violari, Avye
    Cotton, Mark F.
    Panchia, Ravindre
    Dobbels, Els
    Sewraj, Poonam
    van Niekerk, Nadia
    Jean-Philippe, Patrick
    Adrian, Peter V.
    VACCINE, 2013, 31 (05) : 777 - 783
  • [26] Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants
    Gattringer, R.
    Winkler, H.
    Roedler, S.
    Jaksch, P.
    Herkner, H.
    Burgmann, H.
    TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (05) : 540 - 544
  • [27] Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
    Ohshima, Nobuharu
    Akeda, Yukihiro
    Nagai, Hideaki
    Oishi, Kazunori
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (09) : 2285 - 2291
  • [28] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis
    Vadlamudi, Nirma Khatri
    Parhar, Kamalpreet
    Malana, Kim Lorenzo Altre
    Kang, Amy
    Marra, Fawziah
    VACCINE, 2019, 37 (08) : 1021 - 1029
  • [29] Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
    Russell, F. M.
    Licciardi, P. V.
    Balloch, A.
    Biaukula, V.
    Tikoduadua, L.
    Carapetis, J. R.
    Nelson, J.
    Jenney, A. W. J.
    Waqatakirewa, L.
    Colquhoun, S.
    Cheung, Y. B.
    Tang, M. L. K.
    Mulholland, E. K.
    VACCINE, 2010, 28 (18) : 3086 - 3094
  • [30] Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
    Song, Joon Young
    Cheong, Hee Jin
    Tsai, T. F.
    Chang, Hyun-ah
    Choi, Min Joo
    Jeon, Ji Ho
    Kang, Seong Hee
    Jeong, Eun Ju
    Noh, Ji Yun
    Kim, Woo Joo
    VACCINE, 2015, 33 (36) : 4647 - 4652
12345